The Verdict: For weight loss and metabolic correction, GLP-1 agonists are the clinically validated choice
It is therefore relatively simple to produce synthetically and characterize analytically
It may be reasonable to focus on whether the combination of GLP-1RAs and SGLT2is, which are expected to have complementary effects based on large-scale clinical trial results, can further reduce cardiovascular and renal events in patients with diabetes
* Correspondence: Renshi Xu, [email protected] These authors have contributed equally to this work ORCID: Wenzhi Chen, orcid.org/0000-0003-0720-5888
Tuy nhin, nu ch l b vn cc do pha ch sai, hoc bo qun sai cch khin cho bt Whey Protein b m, gy nn tnh trng vn cc, i mu, nhng khng b mc, hay ht hn s dng, th cc bn hon ton c th yn tm v tip tc s dng sn phm, m khng s b thay i v cht lng, hay gy hi cho sc khe trong qu trnh s dng